Abstract:Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of aberrant cells. Thus, RCD pathways represented by apoptosis have increased in importance as a target for the development of cancer medications in recent years. However, because tumor cells show avoidance to apoptosis, which causes treatment resistance and recurrence, numerous studies have been devoted to alternative cancer cell mortality processes, namely necroptosis, pyroptosis, ferroptosis, and cuproptosis; these RCD modalities have been extensively studied and shown to be crucial to cancer therapy effectiveness. Furthermore, evidence suggests that tumor cells undergoing regulated death may alter the immunogenicity of the tumor microenvironment (TME) to some extent, rendering it more suitable for inhibiting cancer progression and metastasis. In addition, other types of cells and components in the TME undergo the abovementioned forms of death and induce immune attacks on tumor cells, resulting in enhanced antitumor responses. Hence, this review discusses the molecular processes and features of necroptosis, pyroptosis, ferroptosis, and cuproptosis and the effects of these novel RCD modalities on tumor cell proliferation and cancer metastasis. Importantly, it introduces the complex effects of novel forms of tumor cell death on the TME and the regulated death of other cells in the TME that affect tumor biology. It also summarizes the potential agents and nanoparticles that induce or inhibit novel RCD pathways and their therapeutic effects on cancer based on evidence from in vivo and in vitro studies and reports clinical trials in which RCD inducers have been evaluated as treatments for cancer patients. Lastly, we also summarized the impact of modulating the RCD processes on cancer drug resistance and the advantages of adding RCD modulators to cancer treatment over conventional treatments.

Non-apoptotic cell death in malignant tumor cells and natural compounds

Non-apoptotic cell death-based cancer therapy: Molecular mechanism, pharmacological modulators, and nanomedicine

Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance

Cell death pathways: molecular mechanisms and therapeutic targets for cancer

Progress in phytochemicals′ induction of autophagic cell death in cancer cells and regulation of nuclear receptors

Pyroptosis induced by natural products and their derivatives for cancer therapy

Natural compounds modulating mitophagy: Implications for cancer therapy

The role of non-apoptotic cell death in the treatment and drug-resistance of digestive tumors

Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy

Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds

Advances in tumor nanotechnology: theragnostic implications in tumors via targeting regulated cell death

Plant-derived natural compounds: A new frontier in inducing immunogenic cell death for cancer treatment

Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis

Paraptosis: a non-classical paradigm of cell death for cancer therapy

Targeting non-apoptotic cell death in cancer treatment by nanomaterials: Recent advances and future outlook

Recent Advances in Nanomaterial‐Mediated Cell Death for Cancer Therapy

Mitochondria‐targeting metallodrugs for cancer therapy: perspectives from cell death modes

Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research

Metabolic cell death in cancer: ferroptosis, cuproptosis, disulfidptosis, and beyond

Targeting paraptosis in cancer: opportunities and challenges